Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
Authors' conclusion
Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.
Study context
- Population
- Participants with T2D from SURPASS-1, SURPASS-2 and SURPASS-3
- Participants
- 3,792 participants
- Comparison
- Early-onset vs later-onset T2D, treated with tirzepatide
- Primary endpoint
- Changes in mean HbA1c, BW, WC, lipids and BP
- Follow-up
- Week 40 (SURPASS-1, −2) or week 52 (SURPASS-3)
Methodological detailssubgroup analysis by age at T2D onset
- Subgroup analysis by age at T2D onset
Primary result
As reported in the abstract
Changes with tirzepatide in SURPASS-2 · week 40
- Similar HbA1c change, early-onset vs later-onset
- −2.6% vs. −2.4%
- Similar body weight (BW) change, early-onset vs later-onset
- −14 vs. −13 kg
- Similar waist circumference (WC) change, early-onset vs later-onset
- −10 vs. −10 cm
- Similar TG change, early-onset vs later-onset
- −26% vs. −24%
- Similar HDL change, early-onset vs later-onset
- 7% vs. 7%
- Similar systolic blood pressure (BP) change, early-onset vs later-onset
- −6 vs. −7 mmHg
Further findings
| Outcome | P value |
|---|---|
| Baseline characteristics in SURPASS-2Early-onset T2D vs Later-onset T2D · Diabetes duration 9 vs. 7 years; longer with early-onset | P < 0.001 |
| Baseline characteristics in SURPASS-2Early-onset T2D vs Later-onset T2D · Glycemic levels 8.5% vs. 8.2%; higher with early-onset | P < 0.001 |
| Baseline characteristics in SURPASS-2Early-onset T2D vs Later-onset T2D · BW 97 vs. 93 kg; higher with early-onset | P < 0.001 |
| Baseline characteristics in SURPASS-2Early-onset T2D vs Later-onset T2D · BMI 35 vs. 34 kg/m²; higher with early-onset | P < 0.001 |
- Baseline characteristics in SURPASS-2 — Similarly abnormal lipid profile; TG, early-onset vs later-onset
- 167 vs. 156 mg/dL
Baseline characteristics in SURPASS-2
- Early-onset participants were younger
Original publication
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →